

ANNEXIN PARTICIPATES IN SEVERAL INVESTOR AND INDUSTRY EVENTS

Annexin Pharmaceuticals AB (publ) today announces that the company will participate in several leading international investor and industry events this summer. The aim is to increase awareness of the company and the drug candidate ANXV, as well as to deepen dialogues with potential partners and investors.

- **BIO International Convention 2025, June 16-19, Boston, USA**
One of the world's largest biotech congresses with participants from the entire pharmaceutical industry.
Read more here: [BIO 2025](#)
- **Clinical Trials at the Summit (CTS) 2025, June 19-22, Las Vegas, USA**
A leading forum for clinical trials in eye diseases, with a focus on innovation and collaboration. Annexin has been selected and invited to present.
Read more here: [Clinical Trials at the Summit 2025](#)
- **Ophthalmology Innovation Source, OIS Retina Innovation Summit 2025, July 29, Long Beach, California, USA**
An exclusive event for innovation in ophthalmology, bringing together leading players in the retina field. Annexin has been selected and invited to present.
Read more here: [OIS Retina Innovation 2025](#)
- **American Society of Retina Specialists, ASRS 2025, July 30 – August 1, Long Beach, California, USA**
Immediately after the above event, eye care specialists will continue to gather to spark new conversations and create opportunities for future collaboration.
Read more here: [ASRS 2025](#)
- **EURETINA 2025, 4-7 September, Paris, France**
Europe's largest scientific congress in retina, focusing on clinical research and new treatments. Annexin has been selected and invited to present.
Read more here: [Euretina 2025](#)

"We look forward to presenting our progress and discussing ANXV's potential with both industry peers and investors at these important meetings. It is part of our strategy to increase the international visibility of our project in retinal vein occlusion (RVO) and other eye diseases," says Anders Haegerstrand, CEO of Annexin Pharmaceuticals.

For further information, please contact:

Anders Haegerstrand, CEO

Phone: +46 70 575 50 37

E-mail: anders.haegerstrand@annexinpharma.com

Anna Frostegård, CSO/CMO

Phone: +46 70 110 42 58

E-mail: anna.frostegard@annexinpharma.com

About Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5. The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.

Attachments

[Annexin participates in several investor and industry events](#)